# Pembrolizumab Plus Neoadjuvant Chemotherapy for Locally Advanced EGJ Adenocarcinoma

> **NCT04813523** · PHASE2 · UNKNOWN · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Adenocarcinoma of Esophagogastric Junction
- Neoadjuvant Chemotherapy
- Pembrolizumab

## Interventions

- **DRUG:** Pembrolizumab Injection [Keytruda]

## Key facts

- **NCT ID:** NCT04813523
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-04-01
- **Primary completion:** 2022-03-31
- **Final completion:** 2024-03-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2021-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04813523

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04813523, "Pembrolizumab Plus Neoadjuvant Chemotherapy for Locally Advanced EGJ Adenocarcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04813523. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*